Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

EPT Disclosure

15 Mar 2010 11:30

RNS Number : 5775I
Piper Jaffray Ltd
15 March 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

Piper Jaffray Ltd.

Company dealt in

Ark Therapeutics Group PLC 

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ord 1p

Date of dealing

12 March 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

122,407 0.06%

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

122,407 0.06%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

 

Total

 

 

(c) Rights to subscribe (Note 2)

 

Class of relevant security:

 

Details

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 4)

Buy

78,000

11.50p

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

 

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

(d) Other dealings (including new securities) (Note 3)

 

Nature of transaction (Note 7)

 

Details

Price per unit (if applicable) (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

 

 

Date of disclosure

15 March 2010

Contact name

Norman Gould

Telephone number

020 3142 8780

Name of offeree/offeror with which connected

Ark Therapeutics Group PLC 

Nature of connection (Note 9)

Adviser and broker

 

 

Notes

 

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMUVUARRWAOAAR
Date   Source Headline
21st Feb 20117:00 amRNSBoard Change
11th Feb 20117:00 amRNSNotice of Results
8th Feb 20117:00 amRNSDisposal of Majority of Woundcare Business
20th Jan 201112:25 pmRNSHolding(s) in Company
4th Jan 20111:19 pmRNSTotal Voting Rights
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20109:40 amRNSBlocklisting Interim Review
29th Nov 20101:06 pmRNSHolding(s) in Company
29th Nov 20107:00 amRNSPositive results for pre-clinical product EG013
11th Nov 20107:00 amRNSInterim Management Statement
8th Nov 20102:21 pmRNSHolding(s) in Company
23rd Sep 20104:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20104:35 pmRNSPrice Monitoring Extension
14th Sep 20104:21 pmRNSHolding(s) in Company
14th Sep 20104:19 pmRNSHolding(s) in Company
13th Sep 20103:29 pmRNSDirector/PDMR Shareholding
9th Sep 20107:00 amRNSStrategic Review
31st Aug 201010:33 amRNSTotal Voting Rights
27th Aug 201010:08 amRNSForm 8.5 (EPT/NON-RI)
25th Aug 20107:00 amRNSHalf Yearly Report
20th Aug 20102:27 pmPRNForm 8.3 - Ark Therapeutics Group Plc
19th Aug 201011:35 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 201012:29 pmRNSForm 8.3 - Ark Therapeutics Group plc
16th Aug 20107:00 amRNSForm 8.3 - Ark Therapeutics PLC (Amendment)
13th Aug 20104:24 pmRNSRe EGM
13th Aug 201011:34 amRNSForm 8.5 (EPT/NON-RI)
13th Aug 201011:22 amRNSForm 8.5 (EPT/RI)
13th Aug 201010:30 amRNSForm 8.3 - Ark Therapeutics PLC
11th Aug 201011:35 amRNSForm 8.3 - [Ark Therapeutics Plc]
5th Aug 201012:31 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Aug 20104:41 pmRNSSecond Price Monitoring Extn
4th Aug 20104:35 pmRNSPrice Monitoring Extension
4th Aug 201010:00 amRNSForm 8.3 - Ark Therapeutics Group
3rd Aug 201010:47 amRNSForm 8.3 - Ark Therapeutics
30th Jul 201011:22 amRNSForm 8.3 - Ark Therapeutics Plc
29th Jul 201010:34 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201011:03 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 201010:36 amRNSHolding(s) in Company
28th Jul 201010:30 amRNSForm 8.3 - Ark Therapeutics
28th Jul 201010:01 amRNSHolding(s) in Company
26th Jul 20102:57 pmRNSForm 8.3 - [Ark Therapeutics]
26th Jul 20102:41 pmPRNForm 8.3 - ARK THERAPEUTICS
26th Jul 201011:37 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:57 amRNSForm 8.5 (EPT/NON-RI)
23rd Jul 201011:15 amRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 20102:34 pmPRNForm 8.3 - Ark Theraputics Plc
22nd Jul 201012:54 pmRNSForm 8.3 - Ark Therapeutics Group plc
22nd Jul 201011:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jul 201010:55 amRNSForm 8.3 - Ark Therapeutics Group Plc
21st Jul 20102:41 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.